T32	Exp 286 302	the pathogenesis
T33	Exp 356 358	We
T34	Exp 379 383	that
T35	Exp 605 630	The physiologic relevance
T36	Exp 668 695	the proliferative advantage
T37	Exp 634 647	this increase
T38	Exp 757 759	We
T39	Exp 771 775	that
T40	Exp 882 884	We
T41	Exp 904 915	the effects
T42	Exp 1030 1059	the transcription factor AP-1
T43	Exp 1129 1138	the level
T44	Exp 1189 1200	the absence
T45	Exp 1355 1364	the level
T46	Exp 1460 1467	the CD2
T47	Exp 1422 1433	This effect
T48	Exp 1600 1604	that
T49	Exp 1661 1665	that
T50	Exp 1540 1565	the constitutive presence
T51	Exp 1613 1635	the proximal AP-1 site
T52	Exp 1639 1656	the IL-2 promoter
T53	Exp 1885 1902	the c-Fos content
T54	Exp 2079 2087	our data
T55	Exp 2096 2100	that
T56	Exp 2112 2127	the composition
T57	Exp 2237 2251	the phenomenon
R2	Coref Anaphora:T48 Antecedent:T58
T1	Protein 89 93	IL-2
T2	Protein 134 139	c-fos
T3	Protein 441 444	PHA
T4	Protein 464 467	CD2
T5	Protein 468 503	lymphocyte function-associated Ag-3
T6	Protein 588 592	IL-2
T7	Protein 820 824	IL-2
T8	Protein 855 859	IL-2
T9	Protein 966 970	IL-2
T10	Protein 996 1001	c-jun
T11	Protein 1006 1011	c-fos
T12	Protein 1106 1111	c-jun
T13	Protein 1142 1147	c-jun
T14	Protein 1171 1174	PHA
T15	Protein 1233 1238	c-fos
T16	Protein 1293 1296	PHA
T17	Protein 1332 1337	c-fos
T18	Protein 1368 1373	c-fos
T19	Protein 1382 1385	PHA
T20	Protein 1464 1467	CD2
T21	Protein 1468 1503	lymphocyte function-associated Ag-3
T22	Protein 1643 1647	IL-2
T23	Protein 1689 1694	c-Jun
T24	Protein 1703 1708	c-Fos
T25	Protein 1741 1744	PHA
T26	Protein 1770 1775	c-Jun
T27	Protein 1794 1799	c-Fos
T28	Protein 1889 1894	c-Fos
T29	Protein 1956 1960	IL-2
T30	Protein 2201 2205	IL-2
T58	Exp 1596 1599	PBL
